Familial hypercholesterolemia is a metabolic disease caused by a mutation in the low-density lipoprotein receptor gene. It carries early atherosclerosis and coronary artery disease risks.
Mehmet Oncul +4 more
doaj +1 more source
Mortality Among Patients With Familial Hypercholesterolemia: A Registry‐Based Study in Norway, 1992–2010 [PDF]
Background Untreated patients with familial hypercholesterolemia are at increased risk of premature cardiovascular death. The primary aim of this study was to investigate whether this is also the case in the statin era.
Retterstøl, Kjetil +7 more
core +1 more source
Prevalence of Hypercholesterolemia and Awareness of Risk Factors, Prevention and Management Among Adults Visiting Referral Hospital in Ethiopia [PDF]
Aychew Kassa Belete,1 Abebe Tarekegn Kassaw,2 Bantie Getnet Yirsaw,3 Birhan Ambachew Taye,3 Samueal Nigatie Ambaw,1 Biset Asrade Mekonnen,4 Ashenafi Kibret Sendekie5 1Department of Sport Science, Faculty of Natural and Computational Science, Woldia ...
Kassaw AT +6 more
core
Antioxidants level in serum of patients with high cholesterol [PDF]
This study included evaluation the relationship between cholesterol and antioxidants level in the human with hypercholesterolemia . Blood of 33 samples were collected from patients with hypercholesterolemia 18 male and 15 female with age ranging between (
Ameera Hamdoon
doaj +1 more source
Hypercholesterolemia is a clinically relevant condition with an ascertained role in atherogenesis. In particular, its presence directly correlates to the risk of atherosclerotic cardiovascular disease (ASCVD).
Pietro Ferrara +3 more
doaj +1 more source
Familial homozygous hypercholesterolemia is a rare autosomal disorder characterized by high levels of cholesterol, extensive tendon xanthomatosis and premature development of atherosclerotic disease. Early coronary artery disease with myocardial infarctions and sudden deaths are common.
Parvaiz A, Koul +4 more
openaire +2 more sources
Efficacy and Safety of Alirocumab as Add-on Therapy in High–Cardiovascular-Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg)::Design and Rationale of the ODYSSEY OPTIONS Studies [PDF]
The phase 3 ODYSSEY OPTIONS studies (OPTIONS I, NCT01730040; OPTIONS II, NCT01730053) are multicenter, multinational, randomized, double-blind, active-comparator, 24-week studies evaluating the efficacy and safety of alirocumab, a fully human monoclonal ...
Peter H. Jones +13 more
core +1 more source
Background and aim: Many children with an FH mutation also exhibit elevated lipoprotein(a) levels, which is an independent risk factor for atherosclerotic cardiovascular disease.
Anja K. Johansen +8 more
doaj +1 more source
Familial hypercholesterolemia: is it time to separate monogenic from polygenic familial hypercholesterolemia? [PDF]
PURPOSE OF REVIEW: This review explores the concepts of monogenic and the so-called polygenic familial hypercholesterolemia and how the identification of familial hypercholesterolemia as a monogenic condition and its separation from polygenic primary ...
Ray, Kausik K +7 more
core +1 more source
Defining Features of Gabriele‐de Vries Syndrome in Adults: A Case Report and Literature Review
ABSTRACT Gabriele‐de Vries syndrome (GADEVS) is a neurodevelopmental disorder caused by heterozygous pathogenic variants in the YY1 gene. Like most rare genetic syndromes, the adult manifestations of GADEVS remain poorly defined. Here, we describe the oldest patient reported to date with GADEVS—a 63‐year‐old woman with a c.1177_1179del YY1 variant ...
Ethan W. Hollingsworth, Changrui Xiao
wiley +1 more source

